Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ERY974 |
Synonyms | |
Therapy Description |
ERY974 is a bispecific antibody targeting both glypican 3 (GPC3) and CD3, which may enhance immune response against GPC3-expressing tumor cells (PMID: 28978751, PMID: 32247040, PMID: 31510063). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ERY974 | ERY-974|ERY 974 | CD3 Antibody 92 GPC3 Antibody 4 | ERY974 is a bispecific antibody targeting both glypican 3 (GPC3) and CD3, which may enhance immune response against GPC3-expressing tumor cells (PMID: 28978751, PMID: 32247040, PMID: 31510063). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02748837 | Phase I | ERY974 | A Study of ERY974 in Patient With Advanced Solid Tumors | Completed | USA | NLD | FRA | 0 |